Sartorius Stedim Biotech Stock
Stocks
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-09-08 EDT
|
After hours 15:08:29 | |||
| 190.40 EUR | +2.09% |
|
189.70 | -0.37% |
| 03:06am | Sartorius Stedim Biotech : Barclays remains its Buy rating | ZD |
| 08-20 | UBS Upgrades Sartorius Stedim Biotech to Buy, Boosts PT | MT |
| Market Cap | 18.15B 21.1B 17.07B 15.58B 29.07B 2,001B 29.22B 202B 78.26B 1,023B 79.25B 77.52B 3,254B | P/E 2026 * |
47.6x | P/E 2027 * | 36.9x |
|---|---|---|---|---|---|
| Enterprise Value | 20.15B 23.44B 18.96B 17.3B 32.29B 2,222B 32.46B 225B 86.92B 1,136B 88.02B 86.1B 3,614B | EV / Sales 2026 * |
6.45x | EV / Sales 2027 * | 5.74x |
| Free-Float |
28.47% | Yield 2026 * |
0.45% | Yield 2027 * | 0.54% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| DIM | Real-time | |
CBOE
| DIMp | Real-time | |
|
Boerse Muenchen
| 56S1 | Real-time | |
|
Tradegate
| 56S1 | Real-time | |
|
OTC Markets
| SDMHF | Delayed | |
|
Börse Stuttgart
| 56S1 | Delayed | |
|
Xetra
| 56S1 | Delayed | |
|
London S.E.
| 0NK7 | Delayed | |
|
Deutsche Boerse AG
| 56S1 | Delayed | |
|
CBOE
| 0NK7 | Real-time | |
|
Borsa Italiana
| 4DIM | End-of-day quote | |
|
Wiener Boerse
| DIM | End-of-day quote |
Last Transcript : Sartorius Stedim Biotech
| 1 day | +2.09% | ||
| 1 week | -2.51% | ||
| Current month | -2.86% | ||
| 1 month | +4.96% | ||
| 3 months | +6.13% | ||
| 6 months | +17.21% | ||
| Current year | -9.33% |
| 1 week | 185 |  | 203 |
| 1 month | 177.7 | | 203 |
| Current year | 150 | | 224 |
| 1 year | 150 | | 224 |
| 3 years | 139.1 | | 281 |
| 5 years | 139.1 | | 551 |
| 10 years | 50.13 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 51 | 2023-03-27 |
| Chief Tech/Sci/R&D Officer | 61 | 2011-09-07 | |
Petra Müller
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 2015-04-06 | |
Susan Dexter
BRD | Director/Board Member | 69 | 2015-04-06 |
Lothar Kappich
BRD | Director/Board Member | 69 | 2017-09-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/17/25 | Sell | Company | 750,000 | 0.7706% | ||
| 2/16/24 | Buy | Chief Executive Officer | 1,716,739 | 1.8624% | ||
| 3/2/22 | Sell | Company | 200,442 | 0.2174% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.09% | -2.51% | +9.33% | -28.02% | 21.1B | |
| -2.51% | -3.02% | -20.09% | +4.88% | 187B | |
| -1.95% | +0.37% | -0.65% | +15.54% | 120B | |
| -1.23% | -1.20% | +9.78% | +84.02% | 63.15B | |
| -3.40% | -5.18% | +13.70% | +44.83% | 52.36B | |
| -2.53% | -3.86% | -6.10% | -32.56% | 50.32B | |
| -3.45% | -5.77% | +8.90% | -18.60% | 33.17B | |
| -4.48% | +0.63% | - | - | 32.1B | |
| -0.50% | -0.37% | +33.28% | -14.19% | 23.93B | |
| -1.98% | -7.53% | -12.06% | +6.09% | 22.7B | |
| Average | -2.03% | -1.13% | +4.01% | +6.89% | 60.67B | |
| Weighted average by Cap. | -2.29% | -0.91% | -3.13% | +12.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.13B 3.64B 2.94B 2.68B 5.01B 345B 5.04B 34.85B 13.48B 176B 13.66B 13.36B 561B | 3.47B 4.03B 3.26B 2.98B 5.56B 382B 5.59B 38.66B 14.96B 195B 15.15B 14.82B 622B |
| Net income | 381M 444M 359M 327M 611M 42.05B 614M 4.25B 1.64B 21.49B 1.67B 1.63B 68.4B | 483M 562M 455M 415M 774M 53.27B 778M 5.39B 2.08B 27.23B 2.11B 2.06B 86.65B |
| Net Debt | 2.01B 2.34B 1.89B 1.72B 3.22B 221B 3.23B 22.38B 8.66B 113B 8.77B 8.58B 360B | 1.76B 2.04B 1.65B 1.51B 2.81B 194B 2.83B 19.57B 7.57B 98.93B 7.67B 7.5B 315B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-08 | €190.40 | +2.09% | 53,269 |
| 26-09-07 | €186.50 | -2.00% | 42,207 |
| 26-09-04 | €190.30 | -4.18% | 63,469 |
| 26-09-03 | €198.60 | +0.35% | 79,897 |
| 26-09-02 | €197.90 | +1.33% | 93,408 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
